| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| 5g |
|
||
| Other Sizes |
|
Purity: ≥98%
Sulfameter (Bayrena; Sulfametoxydiazine; 5-Methoxysulfadiazine; NSC-683528; I-2586; SH-613) is a novel, long-acting sulfonamide antibacterial agent used as a leprostatic agent and also is used to treat UTIs/urinary tract infections. Sulfonamide antibiotics act by blocking the synthesis of dihydrofolic acid via inhibiting the enzyme DHPS/ dihydropteroate synthase. Sulfonamides are active against Gram positive bacteria and Gram negative bacteria. The mode of resistance is via the alteration of dihydropteroate synthase or alternative pathway for folic acid synthesis.
| ln Vitro |
|
||
|---|---|---|---|
| ln Vivo |
|
||
| Animal Protocol |
|
||
| References |
Int J Clin Pharmacol Biopharm.1979 Jun;17(6):260-3;Clin Pharmacol Ther.1969 Jul-Aug;10(4):591-4.
|
||
| Additional Infomation |
Sulfamethoxydiazine is a sulfonamide consisting of pyrimidine having a methoxy substituent at the 5-position and a 4-aminobenzenesulfonamido group at the 2-position. It has a role as an antiinfective agent, a renal agent and a leprostatic drug. It is a member of pyrimidines, a sulfonamide and a sulfonamide antibiotic. It is functionally related to a sulfanilamide.
Long acting sulfonamide used in leprosy, urinary, and respiratory tract infections. Sulfameter is a long-acting sulfonamide antibacterial agent used to treat urinary tract infections and leprosy. Long acting sulfonamide used in leprosy, urinary, and respiratory tract infections. |
| Molecular Formula |
C11H12N4O3S
|
|
|---|---|---|
| Molecular Weight |
280.3
|
|
| Exact Mass |
280.063
|
|
| CAS # |
651-06-9
|
|
| Related CAS # |
Sulfameter-d4;1189483-96-2;Sulfameter-13C6
|
|
| PubChem CID |
5326
|
|
| Appearance |
Typically exists as solid at room temperature
|
|
| Density |
1.5±0.1 g/cm3
|
|
| Boiling Point |
539.4±56.0 °C at 760 mmHg
|
|
| Melting Point |
214-216°C
|
|
| Flash Point |
280.0±31.8 °C
|
|
| Vapour Pressure |
0.0±1.4 mmHg at 25°C
|
|
| Index of Refraction |
1.647
|
|
| LogP |
0.42
|
|
| Hydrogen Bond Donor Count |
2
|
|
| Hydrogen Bond Acceptor Count |
7
|
|
| Rotatable Bond Count |
4
|
|
| Heavy Atom Count |
19
|
|
| Complexity |
368
|
|
| Defined Atom Stereocenter Count |
0
|
|
| SMILES |
S(C1C([H])=C([H])C(=C([H])C=1[H])N([H])[H])(N([H])C1=NC([H])=C(C([H])=N1)OC([H])([H])[H])(=O)=O
|
|
| InChi Key |
GPTONYMQFTZPKC-UHFFFAOYSA-N
|
|
| InChi Code |
InChI=1S/C11H12N4O3S/c1-18-9-6-13-11(14-7-9)15-19(16,17)10-4-2-8(12)3-5-10/h2-7H,12H2,1H3,(H,13,14,15)
|
|
| Chemical Name |
4-amino-N-(5-methoxypyrimidin-2-yl)benzenesulfonamide
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.92 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (8.92 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (8.92 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5676 mL | 17.8380 mL | 35.6761 mL | |
| 5 mM | 0.7135 mL | 3.5676 mL | 7.1352 mL | |
| 10 mM | 0.3568 mL | 1.7838 mL | 3.5676 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT05728229 | Completed | Drug: Supplement with SiderAl® Med | Fatigue Stroke |
Fondazione Policlinico Universitario Agostino Gemelli IRCCS |
November 7, 2022 | Not Applicable |
| NCT00933010 | Completed | Metabolic Syndrome | AstraZeneca | October 2009 | ||
| NCT06182189 | Recruiting | Other: Observation of patients with a benign prostatic hyperplasia condition |
Benign Prostatic Hyperplasia | IRCCS San Raffaele | December 1, 2014 | |
| NCT05431283 | Recruiting | Drug: Tofacitinib | Ulcerative Colitis Spondyloarthropathy |
Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) |
April 25, 2022 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA